The role of Helicobacter pylori in complex human comorbidity

Cover Page

Cite item

Abstract

One of the main features of modern medicine is the fact that the majority of somatic diseases lose their mononosological nature and acquire the status of comorbidity. Examining complex comorbidity is a priority for specialists in various medical disciplines. Accomplishing scientific research and obtaining nessesary data as well as their further comprehension allowed to formulate major directions for investigating a comorbidity issue. Primarily, it concerns studying rate and general patterns for combination of pathologies, determining features of clinical course and strategy for using drug therapy. Comorbidity issue is rarely considered among infectious diseases. It should be understood that a term “comorbidity” refers to the state of the concomitant detection of several diseases. This terminology may and should be applied to combined somatic and infectious pathology envisioned as a complex pathological condition, but with some additions. The term “complex comorbidity”, in our opinion, is also valid both in case of either simultaneous or sequential presence of psychosomatic pathology and monoetiological infection, as well as somatic pathology and polyetiological infection. After H. pylori was discovered, over the past decades a significant number of studies have emerged regarding a role of helicobacter in etiology and pathogenesis of a large number of somatic diseases. The accumulated knowledge has determined that Helicobacteriosis is the most common bacterial infection in human, and H. pylori is considered as the cause for developing pathology of the gastrointestinal tract as well as other host organs and systems. At the current stage in the development of medicine, H. pylori is not only associated with occurrence of gastric and duodenal ulcers, because the microbe-linked pathogenic effect is not limited only to diseases of the gastroduodenal area. Helicobacter pylori infection can be considered as a trigger in emerging somatic pathology such as chronic gastritis, gastric and duodenal ulcer, MALT lymphoma, and gastric adenocarcinoma. These conditions may be referred to the status of complex comorbidity. To date, association links between Helicobacter pylori and idiopathic iron deficiency anemia, as well as idiopathic thrombocytopenic purpura, have been reliably determined. Thus, various clinical aspects of H. pylori infection are heterogeneous and have a wide range of pathological conditions, which evidence base is replenished with data both in terms of pathogenesis and clinical components.

About the authors

A. V. Sergeeva

Privolzhsky Research Medical University of the Ministry of Health of the Russian Federation

Author for correspondence.
Email: sergeeva-av2013@yandex.ru
ORCID iD: 0000-0003-2188-336X

Anzhelika V. Sergeeva - PhD (Medicine), Associate Professor, Head of the Educational Microbiological Laboratory, Department of Epidemiology, Microbiology and Evidence-Based Medicine, Privolzhsky Research Medical University of the Ministry of Health of the Russian Federation.

603950, Nizhny Novgorod, Minin and Pozharsky sqr., 10/1.

Phone: +7 (831) 436-94-81.

SPIN-код: 5893-8275

Russian Federation

V. V. Shkarin

Privolzhsky Research Medical University of the Ministry of Health of the Russian Federation

Email: nn_epidemiolog@pimunn.ru

RAS Corresponding Member, PhD, MD (Medicine), Professor, Consulting Professor of the Department of Epidemiology, Microbiology and Evidence-Based Medicine, Privolzhsky Research Medical University of the Ministry of Health of the Russian Federation.

603950, Nizhny Novgorod, Minin and Pozharsky sqr., 10/1.

SPIN-код: 9382-9086

Russian Federation

O. V. Kovalishena

Privolzhsky Research Medical University of the Ministry of Health of the Russian Federation

Email: kovalishena@mail.ru

PhD, MD (Medicine), Professor, Head of the Department of Epidemiology, Microbiology and Evidence-Based Medicine, Science Director of the Research Institute of Preventive Medicine, Privolzhsky Research Medical University of the Ministry of Health of the Russian Federation.

603950, Nizhny Novgorod, Minin and Pozharsky sqr., 10/1.

SPIN-код: 6190-8703

Russian Federation

References

  1. Балаболкин И.И. Бронхиальная астма у детей. М.: Медицина, 2003. 160 с.
  2. Белялов Ф.Н. Двенадцать тезисов коморбидности // Клиническая медицина. 2009. № 12. С. 69–71.
  3. Верткин Л.Л., Скотников А.С. Коморбидность // Лечащий врач. 2013. № 6. С. 66–69.
  4. Камышникова Л.А., Ефремова О.А., Гусейнли Э.Г. Современный обзор: Helicobacter Pylori и риск развития ишемической болезни сердца // Научный результат. Медицина и фармация. 2016. Т. 2, № 3. С. 3–10. doi: 10.18413/2313-8955-2016-2-3-3-10
  5. Камышникова Л.А., Макарян Б.С. Оценка соблюдения принципов здорового образа жизни в молодом возрасте и оценка риска кардиоваскулярной патологии на примере студентов медицинского института // Научный результат. Медицина и фармация. 2015. № 2. С. 62–68.
  6. Маев И.В. Современные представления о заболеваниях желудочно-кишечного тракта, ассоциированных с Helicobacter pylori // Терапевтический архив. 2006. Т. 78, № 2. С. 10–15.
  7. Маев И.В., Самсонов А.А., Андреев Н.Г., Андреев Д.Н. Важные практические результаты и современные тенденции в изучении заболеваний желудка и двенадцатиперстной кишки // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2012. Т. 4. С. 17–26.
  8. Мазанкова Л.Н., Григорьев К.И. Инфекционные заболевания у детей: роль в возникновении соматической патологии // Детские инфекции. 2013. № 3. С. 3–8.
  9. Мазанкова Л.Н., Захарова И.Н. Инфекционные аспекты соматической патологии у детей // Российский вестник перинатологии и педиатрии. 2010. № 5. С. 8–12.
  10. Насонов Е.Л. Почему необходима ранняя диагностика и лечение ревматоидного артрита? // Русский медицинский журнал. 2002. Т. 10, № 22. С. 1009–1012.
  11. Плахова А.О., Никитина Е.С., Сороцкая В.Н., Каратеева А.Е. Helicobacter pylori как триггерный и отягощающий фактор при ревматоидном артрите и других ревматических заболеваниях // Современная ревматология. 2017. Т. 11, № 2. С. 60–67. doi: 10.14412/1996-7012-2017-2-60-67
  12. Рассохин В.В., Бобрешова А.С. ВИЧ-инфекция и иммуносупрессии. Эпидемиология, клиника и современные стратегии. Тяжелые и коморбидные формы ВИЧ-инфекции // ВИЧ-инфекция и иммуносупрессии. 2017. Т. 9, № 4. С. 106–110. doi: 10.22328/2077-9828-2017-9-4-106-110
  13. Савилов Е.Д., Колесников С.Н., Брико Н.И. Коморбидность в эпидемиологии — новый тренд в исследованиях общественного здоровья // Журнал микробиологии, эпидемиологии и иммунобиологии. 2016. № 4. С. 66–75. doi: 10.36233/0372-9311-2016-4-66-75
  14. Себекина О.В., Трубицына И.Е., Машарова А.А., Дьякова Э.Н. Клинические варианты хронической крапивницы, ассоциированной с Нelicobacter pylori // Экспериментальная и клиническая гастроэнтерология. 2011. № 5. С. 20–25.
  15. Симонова Ж.Г., Мартусевич А.К., Тарловская Е.И. Сочетанная кардиоваскулярная и гастродуоденальная патология. Киров, 2013. 132 с.
  16. Скворцова Е.С., Бородулина Е.А., Осадчук А.М. Инфильтративный туберкулез легких, язвенная болезнь желудка и ВИЧ-инфекция (коморбидность и мультиморбидность заболеваний) // Туберкулез и болезни легких. 2016. Т. 94, № 12. С. 62–66.
  17. Спичак Т.В. Облитерирующий бронхиолит в детском возрасте — это болезнь или синдром? // Педиатрия. Журнал им. Г.М. Сперанского. 2016. Т. 95, № 4. С. 124–130.
  18. Успенский Ю.П., Барышникова Н.В. Helicobacter pylori-ассоциированные заболевания: патогенез, особенности диагностики и дифференцированное лечение: учебно-методическое пособие. СПб.: СПбГМА, 2010. 64 с.
  19. Birnie D., Holme R., McKay I., Hood S., McColl K., Hillis W. Association between antibodies to heat shock protein 65 and coronary atherosclerosis: possible mechanism of action of Helicobacter pylori and other bacterial infections in increasing cardiovascular risk. Eur. Heart J., 1998, vol. 319, pp. 387–394. doi: 10.1053/euhj.1997.0618
  20. Brand P., Baraldi E., Bisgaard H., Boner A.L., Castro-Rodriguez J.A., Custovic A., de Blic J., de Jongste J.C., Eber E., Everard M.L., Frey U., Gappa M., Garcia-Marcos L., Grigg J., Lenney W., Le Souеf P., McKenzie S., Merkus P.J., Midulla F., Paton J.Y., Piacentini G., Pohunek P., Rossi G.A., Seddon P., Silverman M., Sly P.D., Stick S., Valiulis A., van Aalderen W.M., Wildhaber J.H., Wennergren G., Wilson N., Zivkovic Z., Bush A. Definition, assessment and treatment of wheezing disorders in preschool children. Eur. Respir. J., vol. 32, no. 4, pp. 1096–1110. doi: 10.1183/09031936.00002108
  21. Danese S., Zoli A., Cremonini F., Gasbarrini A. High prevalence of Helicobacter pylori type I virulent strains in patients with systemic sclerosis. J. Rheumatol., 2000, vol. 27, no. 6, pp. 1568–1569.
  22. Francis L., Perl A. Infection in systemiclupus erythematosus: friend or foe? Int. J. Clin. Rheumtol., 2010, vol. 5, no. 1, pp. 59–74.
  23. Gasbarrini A., Massari I., Serricchio M., Tondi P., De Luca A., Franceschi F., Ojetti V., Dal Lago A., Flore R., Santoliquido A., Gasbarrini G., Pola P. Helicobacter pylori eradication ameliorates primary Raynaud’s phenomenon. Dig. Dis. Sci., 1998, vol. 43, no. 8, pp. 1641–1645. doi: 10.1023/a:1018842527111
  24. Graff L.B., Andersen L.P., Gernow A., Bremmelgaard A., Bonnevie O., Bondesen S., Danneskiold-Samsøe B., Bartels E.M. Helicobacter pylori and rheumatoid arthritis. J. PreClin. Clin. Res., 2007, vol. 1, pp. 68–73.
  25. Hagymási K., Tulassay Z. Helicobacter pylori infection: new pathogenetic and clinical aspects. World J. Gastroenterol., 2014, vol. 20, no. 21, pp. 6368–6399.
  26. Hamamdzic D., Kasman L.M., LeRoy E.C. The role of infectious agents in the pathogenesis of systemic sclerosis. Curr. Opin. Rheumatol., 2002, vol. 14, no. 6, pp. 694–698. doi: 10.1097/00002281-200211000-00011
  27. Herve F., Cailleux N., Benhamou Y., Ducrotté P., Lemeland J.F., Denis P., Marie I., Lévesque H. Helicobacter pylori prevalence in Raynaud’s disease. Rev. Med. Interne, 2006, vol. 27, no. 10, pp. 736–741. doi: 10.1016/j.revmed.2006.07.003
  28. Ihan A., Pinchuk I.V., Beswick E.J. Inflammation, immunity, and vaccines for Helicobacter pylori infection. Helicobacter, 2012, vol. 17, no. 1, pp. 16–21. doi: 10.1111/j.1523-5378.2012.00977.x
  29. Ismael M.K., Al-Haleem M.R., Salman R.S. Evaluation of anti-Helicobacter pylori antibodies in A group of Iraqi patients with atherosclerosis and coronary artery disease. Iraqi J. Sci., 2015, vol. 56, no. 1A, pp. 81–88.
  30. Kobayashi F., Watanabe E., Nakagawa Y., Yamanishi S., Norose Y., Fukunaga Y., Takahashi H. Production of autoantibodies by murine B-1a cells stimulated with Helicobacter pylori urease through Toll-like receptor 2 signaling. Infect. Immun., 2011, vol. 79, no. 12, pp. 4791–4801. doi: 10.1128/IAI.05808-11
  31. Kusters J.G., van Vliet A.H.M., Kuipers E.J. Pathogenesis of Helicobacter pylori infection. Clin. Microbiol. Rev., 2006, vol. 19, no. 3, pp. 449–490. doi: 10.1128/CMR.00054-05
  32. Magen E., Delgado J.S. Helicobacter pylori and skin autoimmune diseases. World J. Gastroenterol., 2014, vol. 20, no. 6, pp. 1510– 1516. doi: 10.3748/wjg.v20.i6.1510
  33. Malfertheiner P., Megraud F., O’Morain C., Atherton J., Axon A.T., Bazzoli F., Gensini G.F., Gisbert J.P., Graham D.Y., Rokkas T., El-Omar E.M., Kuipers E.J.; European Helicobacter Study Group. Management of Helicobacter pylori infection — the Maastricht IV/Florence consensus report. Gut, 2012, vol. 61, no. 5, pp. 646–664. doi: 10.1136/gutjnl-2012-302084
  34. Marshall B.J., Warren J.R. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet, 1984, vol. 1, no. 8390, pp. 1311–1315. doi: 10.1016/s0140-6736(84)91816-6
  35. Meron M.K., Amital H., Shepshelovich D., Barzilai O., Ram M., Anaya J.M., Gerli R., Bizzaro N., Shoenfeld Y. Infectious aspects and the etiopathogenesis of rheumatoid arthritis. Clin. Rev. Allergy Immunol., 2010, vol. 38, no. 2–3, pp. 287–291. doi: 10.1007/s12016-009-8158-6
  36. Niemelä S., Karttunen T., Korhonen T., Läärä E., Karttunen R., Ikäheino M., Kesaniemi Y.A. Could Helicobacter pylori infection increase the risk of coronary heart disease by modifying serum lipid concentrations? Heart, 1996, vol. 75, no. 6, pp. 573–575.
  37. Patel P., Carrington D., Strachan D.P., Leatham E., Goggin P., Northfield T.C., Mendall M.A. Fibrinogen: a link between chronic infection and coronary heart disease. Lancet, 1994, vol. 343, pp. 1634–1635. doi: 10.1016/s0140-6736(94)93084-8
  38. Patel P., Ghetiya S., Missov E., Sattiraju S. A 3-dimensional transoesophageal echocardiography perspective of mitral valve abscess. J. Geriatr. Cardiol., 2020, vol. 17, no. 2: 124. doi: 10.11909/j.issn.1671-5411.2020.02.009
  39. Peek R.M., Crabtree J.E. Helicobacter infection and gastric neoplasia. J. Pathol., 2006, vol. 208, pp. 233–248. doi: 10.1002/path.1868
  40. Pellicano R., Fagoonee S., Rizzetto M., Ponzetto A. Helicobacter pylori and coronary heart disease: which directions for future studies? Crit. Rev. Microbiol., 2003, vol. 29, no. 4, pp. 351–359. doi: 10.1080/713608015
  41. Radic M., Kaliterna D.M., Bonacin D., Vergles J.M., Radić J., Fabijanić D., Kovačić V. Is Helicobacter pylori infection a risk factor for disease severity in systemic sclerosis? Rheumatol. Int., 2013, vol. 33, no. 11, pp. 2943–2948. doi: 10.1007/s00296-012-2585-z
  42. Regnström J., Jovinge S., Båvenholm P., Ericsson C.G., De Faire U., Hamsten A., Hellenius M.L., Nilsson J., Tornvall P. Helicobacter pylori seropositivity is not associated with inflammatory parameters, lipid concentrations and degree of coronary artery disease. J. Int. Med., 1998, vol. 243, no. 2, pp. 109–113. doi: 10.1046/j.1365-2796
  43. Ruggiero P. Helicobacter pylori infection: what’s new. Curr. Opin. Infect. Dis., 2012, vol. 25, no. 3, pp. 337–344. doi: 10.1097/QCO.0b013e3283531f7c
  44. Sakitani K., Hirata Y., Hayakawa Y., Serizawa T., Nakata W., Takahashi R., Kinoshita H., Sakamoto K., Nakagawa H., Akanuma M., Yoshida H., Maeda S., Koike K. Role of interleukin-32 in Helicobacter pyloriinduced gastric inflammation. Infect. Immun., 2012, vol. 80, no. 11, pp. 3795–3803. doi: 10.1128/IAI.00637-12
  45. Savarino V., Sulli A., Zentilin P., Raffaella Mele M., Cutolo M. No evidence of an association between Helicobacter pylori infection and Raynaud phenomenon. Scand. J. Gastroenterol., 2000, vol. 35, no. 12, pp. 1251–1254. doi: 10.1080/003655200453575
  46. Sawalha A.H., Schmid W.R., Binder S.R., Bacino D.K., Harley J.B. Association between systemic lupus erythematosus and Helicobacter pylori seronegativity. J. Rheumatol., 2004, vol. 31, no. 8, pp. 1546–1550.
  47. Sorrentino D., Faller G., DeVita S., Avellini C., Labombarda A., Ferraccioli G., Kahlow-Toussaint S. Helicobacter pylori associated antigastric autoantibodies: role in Sjögren’s syndrome gastritis. Helicobacter, 2004, vol. 9, no. 1, pp. 46–53. doi: 10.1111/j.1083-4389.2004.00197.x
  48. Sulli A., Seriolo B., Savarino V., Cutolo M. Lack of correlation between gastric Helicobacter pylori infection and primary or secondary Raynaud’s phenomenon in patients with systemic sclerosis. J. Rheumatol., 2000, vol. 27, no. 7, pp. 1820–1821.
  49. Theander E., Nilsson I., Manthorpe R., Jacobsson L.T.H., Wadström T. Seroprevalence of Helicobacter pylori in primary Sjögren’s syndrome. Clin. Exp. Rheumatol., 2001, vol. 19, no. 6, pp. 633–638.
  50. Thieblemont C., Bertoni F., Copie-Bergman C., Ferreri A.J., Ponzoni M. Chronic inflammation and extra-nodal marginal-zone lymphomas of MALT-type. Semin. Cancer Biol., 2014, vol. 24, pp. 33–42. doi: 10.1016/j.semcancer.2013.11.005
  51. Weeks D.L., Eskandari S., Scott D.R., Sachs G. A H+-gated urea channel: the link between Helicobacter pylori urease and gastric colonization. Science, 2000, vol. 287, pp. 482–485.
  52. Wen H., Luo J., Li J., Li X. Helicobacterpylori infection in rheumatic diseases. Arthr. Res. Ther., 2012, vol. 14, no. 1: P74. doi: 10.1186/ar3675
  53. Weydig C., Starzinski-Powitz A., Carra G., Löwer J., Wessler S. CagA-independent disruption of adherence junction complexes involves E-cadherin shedding and implies multiple steps in Helicobacter pylori pathogenicity. Exp. Cell. Res., 2007, vol. 313, no. 16, pp. 3459–3471. doi: 10.1016/j.yexcr.2007.07.015
  54. Yamaguchi K., Iwakiri R., Hara M., Kikkawa A., Fujise T., Ootani H., Shimoda R., Tsunada S., Sakata H., Ushiyama O., Koarada S., Tada Y., Nagasawa K., Fujimoto K. Reflux esophagitis and Helicobacter pylori infection in patients with scleroderma. Intern. Med., 2008, vol. 47, no. 18, pp. 1555–1559.
  55. Yamanishi S., Iizumi T., Watanabe E., Shimizu M., Kamiya S., Nagata K., Kumagai Y., Fukunaga Y., Takahashi H. Implications for induction of autoimmunity via activation of B-1 cells by Helicobacter pylori urease. Infect. Immun., 2006, vol. 74, no. 1, pp. 248–256. doi: 10.1128/IAI.74.1.248-256.2006
  56. Yamaoka Y. Mechanisms of disease: Helicobacter pylori virulence factors. Nature Rev. Gastroenterol. Hepatol., 2010, vol. 7, no. 11, pp. 629–641. doi: 10.1038/nrgastro.2010.154
  57. Yazawa N., Fujimoto M., Kikuchi K., Kubo M., Ihn H., Sato S., Tamaki T., Tamaki K. High seroprevalence of Helicobacter pylori infection in patients with systemic sclerosis: association with esophageal involvement. J. Rheumatol., 1998, vol. 25, no. 4, pp. 650–653.

Supplementary files

There are no supplementary files to display.


Copyright (c) 2021 Sergeeva A.V., Shkarin V.V., Kovalishena O.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies